Nonhuman Primate Pilot Grant Program
Vetrinarians from the Division of Veterinary Medicine at TNPRC perform video assisted thoracoscopic surgery on a rhesus monkey. Minimally invasive endoscopic surgery minimizes surgical morbidity and provides for a more rapid recovery when compared to open surgical techniques.
The most recent submission deadline was in Fall 2014. the NEXT pilot grant competition deadline will be coming up in Fall 2015.
The purpose of this Pilot Program is to facilitate opportunities for research investigators (from Penn, CHOP, Wistar) to utilize the nonhuman primate model of AIDS, our Nonhuman Primate (NHP) Core includes animals and animal support for Penn CFAR developmental studies. The goal of this program is to allow an investigator to accumulate sufficient data and expertise to apply for an independent NIH grant.
Funds are available for the procurement and care of 8 animals (up to 4 animals per project) a year, including appropriate animal laboratory studies (collection of body fluids, biopsies, surgeries, necropsies and basic or SIV-specific laboratory studies). This will permit funding for 1 to 3 projects each year, depending on the number of animals requested, the length of the project, and receipt of competitive applications. Laboratory studies performed at Penn will be the responsibility of the investigator, and there are no funds available for salary support.
All investigators (from Penn, CHOP, Wistar) are eligible for the CFAR pilot funds. If interested, it is required that you contact one of the investigators (listed below) from the Tulane National Primate Research Center (TNPRC) as early as possible to discuss potential studies, study design, and availability of animals.
|Dr. Andrew A. Lackner
|Dr. Preston Marx
|Dr. Ron Veazey
Previous Nonhuman Primate Pilot Projects
|Year||Investigator||Title of Project|
|2012||David Allman, Ph.D.||Long-lived plasma cells in non-human primates|
|2012||Michael P. Cancro, Ph. D., Jean L. Scholz, Ph.D.||Manipulating BLyS as a strategy for relaxing B cell selection to reveal neutralizing specificities in nonhuman primates|
|2011||Sita Awasthi, Ph.D., Harvey Friedman, M.D.||Evaluation of Immunogenicity and efficacy of a HSV-2 trivalent vaccine in macaque model of HSV-2 vaginal infection|
|2011||Beatrice Hahn, M.D., Nick Parrish||Transmissibility of a SIVmac239 Mutant with increased Env content|
|2011||George Shaw, M.D., Ph.D.||Hypermutation in the 5' Untranslated Region (5' UTR) of SIVmac 251/239: A Novel Mechanism of Virus Containment and Escape|
|2010||James Hoxie, M.D.||In vivo studies of a novel CD4-independent variant of SIVmac239|
Una O'Doherty, Ph.D.,
|SIV Reservoir Size and Location in Chinese Rhesus Macaques Progressors and Nonprogressors|
|2010||John Wherry, Ph.D.,
|T-bet-dependent regulation of CD8 T cell exhaustion and PD-expression during SIV infection|
|2009||Robert Doms, M.D., Ph.D.||Zinc finger nuclease-mediated disruption of HIV-1 coreceptors|
|2009||Dennis Kolson, M.D., Ph.D. Francisco Gonzalez-Scarano, M.D.||Oral dimethyl fumarate (BG-12), Funaderm?, an immune modulator and novel candidate central nervous system (CNS) neuroprotectant against SIV/HIV|
|2008||Ronald Collman, M.D.||Gut Microbial Modification in SIV Immune Activation|
|2008||Fred Frankel, Ph.D.||Intranasal Challenge|
|2008||Samuel Parry, M.D. and Preston Marx, Ph.D.||Heterosexual Transmission of HIV: The Uterus as a Critical Target|
|2007||Jean Boyer, Ph.D.||The Impact of Parasitic Infection on AIDS Vaccines|
|2007||Dennis Kolson, M.D., Ph.D. and Kelly Jordan-Sciutto, Ph.D.||The Integrated Stress Response (ISR) in SIV Neuropathogenesis|
|2007||Elena Perez, M.D., Ph.D. and Carl June, M.D.||NHP CCR5 ZFNs Proof of Concept|
|2006||Frederic Bushman, Ph.D.||Lentiviral Infection and Dynamics of the Gut Microbial Flora|
|2005||Luis Montaner, D.V.M., D.Phil. and Andrew Lackner, D.V.M., Ph.D.||TALL-104 Cell Inhibition of SIV Infection|
|2005||David B. Weiner, Ph.D.||Directing Lymphoid Compartments by DNA Vaccines|
|2004||Steven D. Douglas, M.D.||Pilot Study of the Safety, Tolerability, and Pharmacokinetics of Aprepitant, a Neurokinin-1R Receptor Antagonist, in Uninfected and SIV-infected Rhesus Macaques|
|2004||Drew Weissman, Ph.D.||Analysis of Viral and Immune Response in Lymph Nodes of Virologically Suppressed SIV-infected Macaques|